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Abstract 
         This study aims to illustration the role of some important risk factors which including age, age at menarche 
, menopausal status, the levels of estradiol(E2) and luteinizing hormones(LH) in the increasing breast tumors 
incidence by using 120 women, divided into three groups; control group including forty healthy women, benign 
group containing forty women with breast benign tumor and malignant group of forty women with malignant 
breast tumor, this last group subdivided into; malignant presurgery and malignant post surgery groups each one 
contain twenty women.    The results showed that benign breast tumors are  more common in women with 
interval age 31-40 years whereas malignant breast tumors were more common in women with interval age 41-50 
years. Early age at menarche wasn’t significantly associated with increasing breast cancer incidence, 
contrariwise menopausal status which was significantly associated with increasing this disease .   The results 
revealed a significant elevation P≤ 0.05 in the levels of estradiol E2, and Luteinizing hormones in the women 
with breast cancer before tumor excision and reduction in the levels of these hormones in the women after tumor 
excision indicating the role of these hormones in the initiation or promotion breast cancer. 
   In conclusion, this study revealed that breast cancer incidence increased in women in forties and fifties of age 
and increasing the levels of endogenous hormones such as Estradiol, and luteinizing hormones can increased risk 
of developing breast cancer especially in postmenopausal women.   
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1. Introduction 
All cancers start as a single cell that loses control of its normal growth and replication processes and 
they affect many different tissues and types of cells. About 85%of adult cancers which develop from the 
epithelial cells of the inner and outer lining of the body are called carcinomas (American Institute for Cancer 
Research,2007). Generally breast cancer is the second most common cancer after lung cancer 
(WHO,2003).Moreover ,it is the commonest malignancy in females as it constitutes about 3 folds more common 
than all gynecological malignancies put together, and it has become a major health problem in the developed 
world (Horner et al.,2008).Breast cancer a heterogeneous disease that encompasses several distinct entities with 
different biological characteristics and clinical behavior (Carey et al.,2007;Dent et al.,2007). The 2003 world 
health organization (WHO) classification of breast tumor which includes benign (harmless) tumors and 
malignant (cancerous )tumors(Peter et al.,2003).  
Breast cancer is influenced by multiple risk factors which can be classified into four groups (Abulkhair et al., 
2010). These groups are: first reproductive factor such as age at menarche, age at menopause, age at first 
pregnancy and lactation (Veronesi et al., 2005). Second is genetic and family history (Raicevic and Radulovic, 
2000). Third is a history of benign proliferative breast diseases (Wang et al., 2004) . Fourth include obesity, diet, 
al-cohol intake and smoking (International Agency for Research on Cancer, 2002).   
2. Materials and methods:  
2.1 Sampling of cases.   
(a) Study group : forty cases of female patients with breast carcinoma were included in this study ,their 
ages ranging from 25 to 70 years .Twenty cases of these patients were in early detection of breast cancer .The 
other twenty cases were post-excision tumor patients . 
(b) Comparative group: forty cases of female patients with benign breast tumor were included in this 
study, their ages ranging from 15 to 50 years to compare them with malignant and normal breast patients. 
(c) Control group : forty cases of normal females which were healthy and don’t undergo from any 
breast diseases or other diseases .these cases were of the same age of malignant group 
2.2  Collection of blood samples. 
Blood samples were collected from healthy control, benign and malignant patients according to the method 
which used by (Dorgan et al.,2010) 
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2.3  Measurement of   hormones 
  Reagents of estradiol hormone (E2) according to estradiol hormone kit , DRG, Germany. Reagents of 
luteinizing hormone (LH) according to luteinizing hormone kit , Monobind, USA. 
3. Results 
3.1 Age  
The highest percentage of malignant patients in this study was recorded in (41-50 years) with 12 cases (30%) 
followed by 11 cases (27.5%) were seen (31-40 y), 9 cases (22.5%) were seen in (51-60 y),and  7 cases (17.5%) 
were seen in (61-70 y),while only one case (2.5%) was noted in (21-30) and there was no cases recorded in ≤20 
years .In benign tumor patients the highest percentage was noted in (31-40 y) with 13 cases (32.5%) ,while the 
lowest percentage  in (41-50 y) with 6 cases (15%). The interval age ≤20 years recorded 11 cases (27.5%) which 
revealed increasing in compared with 10 cases (25%) in (21-30y). While there was no case recorded in age  (51-
60 y),(61-70 y) respectively which reflect the tendency of benign tumor incidence in younger age . As shown in 
figure (1) 
3.2 Age at menarche. 
Table (1) shows the percentage of women who begin menarche at age more than 12 years in malignant(80%) 
,benign(92.5%) breast tumor and control (85%)  groups recorded prevalence ,while women of the same groups 
above who begin menarche at age less than 12 years have little percentage(20%,7.5%,15%)respectively. 
3.3 Menopausal status .  
The results of table (2) showed that the women who are premenopause in malignant group have less percentage 
14(35%) in comparing with control 18(45%) and benign groups 37(92.5),while postmenopausal women in 
malignant group recorded higher percentage 26(65%) than those of control 22(55%)and benign groups 3(7.5%). 
Benign group showed a significant difference P≤0.05 when being compared with control group, malignant group 
showed a significant difference P≤0.05 as compared with benign group .  
 3.4  Estradiol hormone  (E2). 
  The results of figure (2) showed a highly significant difference P≤0.000 in the levels of estradiol hormone E2 as 
compared with the studied groups ,the levels of this hormone in malignant presurgery group(98.30±75.10) was 
the highest followed by benign group (63.32±31.99) then control group(41.57±30.33) and finally malignant 
postsurgery group(29.60±20.33).Table (3) explains multiple comparisons in serum estradiol hormone levels 
among study population .When the comparison was set between control  and benign groups ,the result records  a 
significant difference P≤0.017 ,there was highly significant difference P≤0.000 between control and malignant 
presurgery groups and the results show no a significant difference P≤0.281 between malignant postsurgery and 
control groups .The results record high significant difference (P≤0.002 and P≤0.003)respectively in comparison 
between benign versus malignant presurgery and benign  versus malignant postsurgery groups. Finally the 
comparison between malignant presurgery and postsurgery was highly significant  P≤0.000. 
3.5  Luteinizing hormone . 
The results of figure (3) proves that a highly significant difference P≤0.001 in  the level of luteinizing hormone 
as compared among studied groups .This table explains that the level of luteinizing hormone when measured in 
forty healthy women was 1.56±0.80  ,while when being measured in forty benign breast tumor women there was 
slight increasing 2.87±2.08  ,whereas the level of the same hormone revealed marked increasing 4.78±2.12  as 
measured in twenty women with breast cancer before surgery then recorded decreasing in it's level 3.64±1.46  in 
twenty women with breast cancer after surgery. Table (4) shows multiple comparisons among studied groups 
,first studied group reveals highly significant difference P≤0.001 as compared with malignant presurgery group 
while in the same first group there was no a significant difference (P≤0.615, P≤0.247) respectively between 
control versus benign and control versus malignant postsurgery groups .With regard to second group in which 
there were two comparisons the first was with significant difference P≤0.000 between benign and malignant 
presurgery groups. The second comparison was without significant difference P≤0.118 between benign versus 
malignant postsurgery. Last comparison was between malignant presurgery and malignant postsurgery exhibits 
no a significant difference P≤0.042.    
4. Discussion  
4.1  Age 
In the present study maximum number of women with malignant breast cancer were observed in 41-50 
years (12 cases) followed by 51-60 years (11 cases) .The average age was 49.1 years .These results agreed with 
previous studies in Iraq  (Waheda, 1998 ; Madhoor ,2002),(figure 1). Age is the single most important risk factor 
in breast cancer. Compared with women in their twenties, women are 10 times as likely to develop breast cancer 
in  their thirties ,40 times as likely in their forties ,60 times as likely in their fifties and 90 times as likely after 
sixties (Forbes, 1997). 
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4.2  Age at menarche  
The association between breast cancer risk and the age at menarche is consistent with the hypothesis;  breast 
cancer risk is related to the total extent of breast mitotic activity which driven by estrogen exposure during the 
luteal phase of menstrual cycle which will determine the probability of tumorigenic somatic events (Pike et 
al.,1993).   The results of this study showed only 20% of women in malignant group and 7.5% women in benign 
group whose age at menarche began before 12 years while the remaining women in malignant and benign groups 
their age at menarche began after 12 years, table (1) .Our results supported by (Chang-Claude et al.,2007 ; 
Barnett et al.,2008) who showed that no association between breast cancer risk and age at menarche. 
4.3 Menopausal status  
The results of the present study show among study population there were 92.5% of women in benign group were 
premenopause  as compared with 35% with same feature in malignant group, table (2) .This result indicates that 
benign breast diseases were more often found in premenopausal women as (Ernster,1981;Bodian et al.,1993) did 
. The rate of fibroadenoma (which was included the most important condition in breast benign diseases) rises to 
75% for biopsies in women under age twenty years (Greenberg et al.,1998) . On other hand the results of this 
study revealed that postmenopausal women in malignant group recorded high prevalence (65%) in comparing 
with benign group which recorded only (7.5%), table (2) , this result was in parallel with(National Breast Cancer 
Coalition (NBCC),1999) which appeared that breast cancer occurs more often in postmenopausal women about 
75% of cases. The increasing in the risk which associated with this menopausal status may be explained possibly 
due to the increased levels of circulating estradiol hormone and reduced level of sex hormone binding globulin 
by the conversion of androgens to estradiol in adipose tissues (Calle and Kaaks,2004). 
4.4 Estradiol hormone (E2)  
 The present study demonstrated that there was a significant increasing in the levels of serum estradiol hormone 
in malignant presurgery women, figure (2) and this result was supported by Blair (2010) who explained that the 
postmenopausal women with elevated plasma or serum estrogen hormone are at increased risk of developing 
breast cancer. Estrogen can cause cancer by stimulating cell proliferation(promotion) and causing genotoxic 
damage(initiation), estrogen are highly mitogenic in hormone sensitive tissues such as breast ,prolonged 
exposure of target tissues and cells to excessive mitogenic stimulation by estrogens has been considered an 
important etiological factor for induction breast cancer (Hiraku et al.,2001).The result of this study was revealed 
a significant difference P≤0.017 when comparison made between control and benign groups, table(3) ,these 
result was supported by Khanna et al. (2012) who found that serum estradiol hormone significantly higher in 
women with breast benign diseases than in normal control. It has been postulated that both benign and malignant 
breast tumor have a hormonal origin because of estradiol hormone profound stimulatory influence on breast 
ductal epithelium and it was thought that it must play a central role in this disease (Wu et al.,1999).  
4.5  Luteinizing hormone (LH) . 
The results show a significant increasing in the levels of serum luteinizing hormone in the women in malignant 
presurgery group, figure (3) ,this result was confirmed by a study explaining the presence of direct effects of LH 
on breast cells themselves (Guo et al.,2004) , there was elevation in the levels of serum LH among 
postmenopausal women with breast cancer as Krishnamoorthy et al.(1994) found. How luteinizing hormone and 
it's receptors exert their effects on breast cancer cells is unclear ,however, one possibility may explain these 
effects which refer to that effects take place through luteinizing hormone receptors which present in the ovaries 
thereby influencing steroid hormone production , another possibility is that effects happen through luteinizing 
hormone receptors present in malignant tumor cells as some studies have detected these receptors in both normal 
and neoplastic breast tissues and in breast cancer cell lines (Kuijper et al.,2009). As luteinizing hormone (LH) 
and luteinizing hormone receptors (LHR) are both involved in estradiol hormone synthesis , functionally 
important polymorphisms in these genes could alter the levels of estrogen exposure and thereby contribute to 
breast cancer risk determination (Powell et al.,2003). 
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Control group Benign group Malignant group 
χ2 No. % No. % No. % 
≤12 6 15 3 7.5 8 20 
2.583 ≥ 12 34 85 37 92.5 32 80 
Total 40 100 40 100.0 40 100.0 
 
 
Table (2) Distribution of control, benign and malignant breast tumor groups according to menopausal 
status .  
Menopausal status 
Control group Benign group Malignant group 
χ2 
No . % No . % No. % 
Premenopause 18 45 37 92.5 14 35  30.638 a c 
Postmenopause 22 55 3 7.5 26 65 
Total 40 100 40 100.0 40 100.0 
a= significant differences when comparing benign with control group at P<0.05                                 c= 
significant differences when comparing malignant with benign group at P<0.05 
 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol 14, 2013 
 
96 
Table (3) Result of multiple comparisons of estradiol hormone  among control, benign and malignant (pre 
and postsurgery) groups 
Studied group Groups P. value Sig . 
Control 
 
Benign 0.017 Significant at <0.05 
Malignant presurgery 0.000 Highly significant at <0.05 





Malignant presurgery 0.002 Highly significant at<0.05 
Malignant postsurgery 0.003 Highly significant at <0.05 
Malignant presurgery Malignant postsurgery 0.000 Highly significant at <0.05 
 
 
Table (4) Result of multiple comparisons of luteinizing hormone  among control, benign and malignant 
(pre and postsurgery)groups 
Studied group  Groups  P. value  Sig . 
Control  Benign  0.615 Non significant at<0.05 
Malignant presurgery  0.001 Highly significant at<0.05 





Malignant presurgery  0.000 Highly significant at<0.05 
Malignant postsurgery  0.118 Non significant at<0.05 
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         *= Significant difference at P≤0.05 
       Figure (2): Serum estradiol hormone levels (E2) (pg/ml)  in control, benign and malignant (pre and 



































*= Significant difference at P≤0.05 
Figure (3): Serum luteinizing hormone levels (µIU/ml) in control, benign and malignant (pre and 
postsurgery)groups. 
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